Necessity to screen and treat latent tuberculosis before ruxolitinib treatment—Ruxolitinib-associated disseminated tuberculosis: A case report and literature review

Ruxolitinib, a Janus kinase inhibitor, considerably improves symptoms of patients with polycythemia vera and primary or secondary myelofibrosis. However, its association with the development of infectious complications is a concern. Herein, we report the case of an 80-year-old man with primary myelo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirai, Nobuyasu, Kasahara, Kei, Yoshihara, Shingo, Nishimura, Tomoko, Omori, Keitaro, Ogawa, Yoshihiko, Ogawa, Taku, Hishiya, Naokuni, Suzuki, Yuki, Yano, Hisakazu, Yoshikawa, Masahide, Mikasa, Keiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332526/
https://www.ncbi.nlm.nih.gov/pubmed/32642438
http://dx.doi.org/10.1016/j.idcr.2020.e00892

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332526/
https://www.ncbi.nlm.nih.gov/pubmed/32642438
http://dx.doi.org/10.1016/j.idcr.2020.e00892

Ejemplares similares